ArticleInternational urology and nephrology2022
Acute kidney injury in hospitalized COVID-19 patients.
Article in International urology and nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Global geographic and socioeconomic disparities in COVID-associated acute kidney injury: a systematic review and meta-analysis.Journal of global health · 2025Pooled it
- Acute kidney injury outcomes in covid-19 patients: systematic review and meta-analysis.Jornal brasileiro de nefrologiaPooled it
- Prevalence and Risk Factors for Acute Kidney Injury in COVID-19-Hospitalized Patients in Poland Across Three Pandemic Periods.Journal of clinical medicine · 2025Article
- Article
- The Effect of COVID-19 Infection on Clinical Outcomes in Patients Undergoing Surgical Repair of Humerus Fractures.Cureus · 2024Article
- The measurement of basal creatinine and the diagnosis of AKI with COVID-19.International urology and nephrology · 2023Article
- Should we continue to use renin-angiotensin-aldosterone system blockers in patients with COVID-19?Clinical kidney journal · 2022Article
- Post-acute COVID-19 syndrome and kidney diseases: what do we know?Journal of nephrology · 2022Review
- Long-term effect of COVID-19 infection on hemodialysis patients: Should we follow hemodialysis patients more closely?Clinical kidney journal · 2022Article
- COVID-19 and acute or chronic kidney disease: a crescent learning.Jornal brasileiro de nefrologiaArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) in COVID-19 patients is associated with poor prognosis. However, the incidence, risk factors and potential outcomes of AKI in hospitalized patients are not well studied. MATERIALS AND
methodsThis is a retrospective cohort study conducted in two major university hospitals. Electronic health records of the patients, 18 years or older, hospitalized between 13 April and 1 June 2020 with confirmed COVID-19 were reviewed. We described the incidence and the risk factors for AKI development in COVID-19 patients. Furthermore, we investigated the effects of AKI on the length of hospital and intensive care unit (ICU) stay, the admission rates to ICU, the percentage of patients with cytokine storm and in-hospital mortality rate.
resultsAmong 770 hospitalized patients included in this study, 92 (11.9%) patients developed AKI. The length of hospitalized days (16 vs 9.9, p < 0.001) and days spent in the hospital until ICU admission (3.5 vs. 2.5, p = 0.003) were higher in the AKI group compared to patients without AKI. In addition, ICU admission rates were also significantly higher in patients with AKI (63% vs. 20.7%, p < 0.001). The percentage of patients with AKI who developed cytokine storm was significantly higher than patients without AKI (25.9% vs. 14%, p = 0.009). Furthermore, the in-hospital mortality rate was significantly higher in patients with AKI (47.2% vs. 4.7%, p < 0.001).
conclusionsAKI is common in hospitalized COVID-19 patients. Furthermore, we show that AKI increases the admission rates to ICU and in-hospital mortality. Our findings suggest that AKI should be effectively managed to prevent the adverse outcomes in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.